

HOUSE RESOLUTION NO. 30

Reps. Morse, Tyrone Carter, Churches, Fitzgerald, Haadsma, Hood, Hope, Rheingans, Rogers, Schuette, Wilson and Young offered the following resolution:

1 A resolution to declare February 2023 as Cholangiocarcinoma
2 Awareness Month in the state of Michigan.

3 Whereas, Cholangiocarcinoma starts in the bile duct, a thin
4 tube, about 4 to 5 inches long, that reaches from the liver to the
5 small intestine. (The major function of the bile duct is to move a
6 fluid called bile from the liver and gallbladder to the small
7 intestine, where it helps digest the fats in food.); and

8 Whereas, There are three types of cholangiocarcinoma:
9 intrahepatic, extrahepatic and perihilar. The mortality rate has
10 increased dramatically in the last decade; and

1 Whereas, An estimated 10,000 people in the United States
2 develop cholangiocarcinoma each year and almost 2 out of 3 people
3 with cholangiocarcinoma are 65 or older when it is found; and

4 Whereas, The chances of survival for patients with bile duct
5 cancer depends to a large extent on its location and how advanced
6 it is when it is found; and

7 Whereas, Patients are typically diagnosed at a late stage due
8 to no validated early method of detection. Symptoms of jaundice,
9 abdominal pain, itchy skin, and weight loss are symptoms that do
10 not usually present until advanced disease progression; and

11 Whereas, Cholangiocarcinoma is a rare cancer. Of the top 8
12 deadliest cancers, 7 are rare. Rare cancers have a 5-year survival
13 rate under 50% with the cholangiocarcinoma 5-year survival rate
14 being approximately 20%; and

15 Whereas, There is currently no cure for
16 cholangiocarcinoma/bile duct cancer; and

17 Whereas, Founded in 2006, in Salt Lake City, Utah, by a family
18 who lost a loved one to cholangiocarcinoma, the Cholangiocarcinoma
19 Foundation has grown to become the leading global resource in
20 research, education, and public awareness; and

21 Whereas, Foundations, research and teaching hospitals, rare
22 cancer advocacy groups, and patient advocacy groups from around the
23 globe have joined forces to recognize February as
24 Cholangiocarcinoma Awareness Month; and

25 Whereas, Increased cholangiocarcinoma advocacy, awareness,
26 research, and education will bring improved outcomes for patients
27 in earlier detection and treatment and potential curative methods;

28 Whereas, The U.S. Food & Drug Administration approved
29 durvalumab (Imfinzi) creating a new standard of care for

1 cholangiocarcinoma patients with the combination of immunotherapy
2 and chemotherapy;

3 Whereas, This body encourages all citizens to educate
4 themselves about the disease by visiting cholangiocarcinoma.org and
5 signing a pledge to help raise awareness in support of
6 Cholangiocarcinoma Awareness Month and residents to remain
7 committed to the continued support of research for treatment and a
8 cure of cholangiocarcinoma; now, therefore, be it

9 Resolved by the House of Representatives, That the members of
10 this legislative body declare February 2023 as Cholangiocarcinoma
11 Awareness Month in the state of Michigan. We recognize all patients
12 and caregivers impacted by this rare, lethal condition.